KUALA LUMPUR: Malaysian Genomics Resource Centre Bhd
is optimistic that its efforts in cell therapy, genetic screening and clinical trials are foundational for its future growth and sustainability.
"In fact, prospects for Malaysian Genomics remain robust. The group is well-positioned as a leading provider of genetic screening, genome analysis, and biopharmaceutical products and services in Southeast Asia.
"By utilising our advanced facilities, including a high-throughput sequencing lab, microarray facility, and state-of-the-art BSL-2 cell processing lab approved by Ministry of Health (MOH), we are dedicated to delivering precision and personalised healthcare solutions," said executive chairman Azri Azerai in a statement.
He added that the group is looking to expand its distribution network via engagement with strategic partners across Southeast Asia, the Middle East North Africa region and the US.
Meanwhile, the group is also leveraging its expertise to develop a range of products for the FMCG market including novel ingredients and finished products for cosmeceuticals, wound healing, and genetic-based fitness improvement programmes.
In the quarter ended Sept 30, 2023, Malaysian Genomics reported a net loss of RM1.45mil as compared to a net profit of RM847,000 in the same quarter in the previous year.
The group's revenue narrowed to RM2.27mil from RM3.81mil in the previous comparative quarter, partly due to a shift in sales focus from immunotherapy to cell therapies, which now constitute approximately 78% of the total revenue.
